Diabetic Neuropathy

Diabetic peripheral neuropathy (DPN) is the most prevalent complication of diabetes mellitus. The prevalence of DPN ranges from 21.3 to 34.5% in type 2 DM and between seven to 34.2% in type 1 DM. Of these, up to 45% of patients with type 2 DM and 54% with type 1 DM could be asymptomatic.

It is estimated that around half of the diabetic population develop painful diabetic neuropathy ranging from mild to debilitating. The existing frontline treatments for pain are ineffective for many and opioids for pain management there huge risks for addiction, overdose and death. Todays world is facing the devastating consequences of the opioid abuse including the rising incidence of new-borns experiencing withdrawal syndrome due to misuse during pregnancy.

It is estimated that around half of the diabetic population develop painful diabetic neuropathy ranging from mild to debilitating. The existing frontline treatments for pain are ineffective for many and opioids for pain management there huge risks for addiction, overdose and death.

Today’s world is facing the devastating consequences of the opioid abuse including the rising incidence of new-borns experiencing withdrawal syndrome due to misuse during pregnancy.

Our Solutions

Multi-targeted ligands with, Neuroprotection as the anchor-Using a neuroprotective/regenerative target as the anchor, we chose an analgesia-driving partner target to design peptide agonists that modulate both. The selected pathways are completely opiate receptor independent. The designed ligands have shown potent target engagement in vitro that translated to strong analgesia in vivo in an acute pain model. Molecules are being developed towards both acute and chronic pain.

Multi-targeted ligands with, Neuroprotection as the anchor-

using a neuroprotective/regenerative target as the anchor, we chose an analgesia-driving partner target to design peptide agonists that modulate both. The selected pathways are completely opiate receptor independent. The designed ligands have shown potent target engagement in vitro that translated to strong analgesia in vivo in an acute pain model. Molecules are being developed towards both acute and chronic pain.